Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Retrovirology ; 10: 162, 2013 Dec 26.
Artículo en Inglés | MEDLINE | ID: mdl-24369910

RESUMEN

BACKGROUND: Previous studies suggest that active selection limits the number of HIV-1 variants acquired by a newly infected individual from the diverse variants circulating in the transmitting partner. We compared HIV-1 envelopes from 9 newly infected subjects and their linked transmitting partner to explore potential mechanisms for selection. RESULTS: Recipient virus envelopes had significant genotypic differences compared to those present in the transmitting partner. Recombinant viruses incorporating pools of recipient and transmitter envelopes showed no significant difference in their sensitivity to receptor and fusion inhibitors, suggesting they had relatively similar entry capacity in the presence of low CD4 and CCR5 levels. Aggregate results in primary cells from up to 4 different blood or skin donors showed that viruses with envelopes from the transmitting partner as compared to recipient envelopes replicated more efficiently in CD4+ T cells, monocyte derived dendritic cell (MDDC) - CD4+ T cell co-cultures, Langerhans cells (LCs) - CD4+ T cell co-cultures and CD4+ T cells expressing high levels of the gut homing receptor, α4ß7, and demonstrated greater binding to α4ß7 high / CD8+ T cells. These transmitter versus recipient envelope virus phenotypic differences, however, were not always consistent among the primary cells from all the different blood or skin donation volunteers. CONCLUSION: Although genotypically unique variants are present in newly infected individuals compared to the diverse swarm circulating in the chronically infected transmitting partner, replication in potential early target cells and receptor utilization either do not completely dictate this genetic selection, or these potential transmission phenotypes are lost very soon after HIV-1 acquisition.


Asunto(s)
Composición Familiar , Infecciones por VIH/transmisión , VIH-1/clasificación , VIH-1/aislamiento & purificación , Heterosexualidad , Integrinas/metabolismo , Productos del Gen env del Virus de la Inmunodeficiencia Humana/genética , Linfocitos T CD4-Positivos/virología , Linfocitos T CD8-positivos/virología , Células Cultivadas , Técnicas de Cocultivo , Estudios de Cohortes , Células Dendríticas/virología , Femenino , Infecciones por VIH/virología , VIH-1/genética , Humanos , Macrófagos/virología , Masculino , Receptores del VIH/metabolismo , Selección Genética
2.
J Infect Dis ; 206(9): 1433-42, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22997233

RESUMEN

BACKGROUND: A genetic bottleneck is known to exist for human immunodeficiency virus (HIV) at the point of sexual transmission. However, the nature of this bottleneck and its effect on viral diversity over time is unclear. METHODS: Interhost and intrahost HIV diversity was analyzed in a stable population in Rakai, Uganda, from 1994 to 2002. HIV-1 envelope sequences from both individuals in initially HIV-discordant relationships in which transmission occurred later were examined using Sanger sequencing of bulk polymerase chain reaction (PCR) products (for 22 couples), clonal analysis (for 3), and next-generation deep sequencing (for 9). RESULTS: Intrahost viral diversity was significantly higher than changes in interhost diversity (P < .01). The majority of HIV-1-discordant couples examined via bulk PCR (16 of 22 couples), clonal analysis (3 of 3), and next-generation deep sequencing (6 of 9) demonstrated that the viral populations present in the newly infected recipient were more closely related to the donor partner's HIV-1 variants found earlier during infection as compared to those circulating near the estimated time of transmission (P = .03). CONCLUSIONS: These findings suggest that sexual transmission constrains viral diversity at the population level, partially because of the preferential transmission of ancestral as opposed to contemporary strains circulating in the transmitting partner. Future successful vaccine strategies may need to target these transmitted ancestral strains.


Asunto(s)
Variación Genética , Infecciones por VIH/transmisión , Infecciones por VIH/virología , VIH-1/clasificación , VIH-1/patogenicidad , Adolescente , Adulto , Análisis por Conglomerados , Femenino , VIH-1/genética , VIH-1/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Filogenia , Reacción en Cadena de la Polimerasa , ARN Viral/genética , Selección Genética , Análisis de Secuencia de ADN , Uganda , Adulto Joven
3.
AIDS Res Hum Retroviruses ; 28(12): 1584-93, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22650962

RESUMEN

As HIV-1 evolves over the course of infection, resistance against antiretrovirals may arise in the absence of drug pressure, especially against receptor and fusion blockers because of the extensive changes observed in the envelope glycoprotein. Here we show that viruses from the chronic phase of disease are significantly less sensitive to CCR5 receptor and fusion blockers compared to early infection variants. Differences in susceptibility to CCR5 antagonists were observed in spite of no demonstrable CXCR4 receptor utilization. No significant sensitivity differences were observed to another entry blocker, soluble CD4, or to reverse transcriptase, protease, or integrase inhibitors. Chronic as compared to early phase variants demonstrated greater replication when passaged in the presence of subinhibitory concentrations of fusion but not CCR5 receptor inhibitors. Fusion antagonist resistance, however, emerged from only one chronic phase virus culture. Because sensitivity to receptor and fusion antagonists is correlated with receptor affinity and fusion capacity, respectively, changes that occur in the envelope glycoprotein over the course of infection confer greater ability to use the CCR5 receptor and increased fusion ability. Our in vitro passage studies suggest that these evolving phenotypes increase the likelihood of resistance against fusion but not CCR5 receptor blockers.


Asunto(s)
Fármacos Anti-VIH/farmacología , Farmacorresistencia Viral , Inhibidores de Fusión de VIH/farmacología , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , Receptores CCR5/metabolismo , VIH-1/crecimiento & desarrollo , VIH-1/aislamiento & purificación , Humanos , Receptores del VIH/metabolismo , Pase Seriado
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA